Success Stories

Event Videos

Plasma Interferon-gamma-Inducible Protein-10 (IP-10) Levels During Acute Hepatitis C Virus Infection Hepatology. 2013 Jun;57(6):2124-34 Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, Zang G, Shaw I, Yeung B, George J, Teutsch S, Kaldor JM, Cherepanov V, Bruneau J, Shoukry NH, Lloyd AR, Dore GJ. http://www.ncbi.nlm.nih.gov/pubmed/23325615 Systemic levels of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment- induced clearance in chronic hepatitis C virus (HCV). In the present study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in three cohorts of acute HCV Published on: Jun-2013 Read more	Immunosuppression and HBV Reactivation Semin Liver Dis. 2013 May;33(2):167-77 Shouval D, Shibolet O. http://www.ncbi.nlm.nih.gov/pubmed/23749673 Hepatitis B virus (HBV) reactivation following immunosuppression is defined by an abrupt rise in HBV replication followed by laboratory signs of hepatocellular injury in a “silent” hepatitis B surface antigen (HBsAg) carrier. Reactivation can also occur, albeit at a lower rate, in patients with occult HBV infection. The clinical presentation of reactivation is variable ranging from an asymptomatic course to severe hepatitis, liver failure, and death. It is most frequently observed in patients with lymphoma treated Published on: May-2013 Read more
Association of Tattooing and Hepatitis C Virus Infection: A Multicenter Case-Control Study Hepatology. 2013 Jun;57(6):2117-23 Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. http://www.ncbi.nlm.nih.gov/pubmed/23315899 Although injection drug use (IDU) and blood transfusions prior to 1992 are well-accepted risk factors for hepatitis C virus (HCV) infection, many studies that evaluated tattooing as a risk factor for HCV infection did not control for a history of IDU or transfusion prior to 1992. In this large, multicenter, case-control study, we analyzed demographic and HCV Published on: Jun-2013 Read more	New Therapeutic Targets and Drugs for the Treatment of Chronic Hepatitis B Semin Liver Dis. 2013 May;33(2):130-7 Fletcher SP, Delaney WE 4th. http://www.ncbi.nlm.nih.gov/pubmed/23749669 Chronic hepatitis B virus (CHB) is managed effectively with either nucleoside/nucleotide- based or interferon-based therapies. However, most patients receiving these therapies do not establish long- Published on: May-2013 Read more
Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Am J Gastroenterol. 2013 Jun;108(6):949-51. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Terrault N. http://www.ncbi.nlm.nih.gov/pubmed/23735916 Abstract Published on: Jun-2013 Read more	Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level. J Pediatr Gastroenterol Nutr. 2013 Feb;56(2):145-50. doi: 10.1097/MPG.0b013e3182722aee. Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level. Huang SC, Yang YJ. Source Department of Pediatrics, Kuo General Hospital, Tainan, Taiwan. Abstract OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is identified as a major liver disease in children. The present study aimed to identify the prevalence and predictors of pediatric NAFLD and the correlation between serum retinol-binding protein 4 (RBP4) levels and metabolic characteristics in children. METHODS: Published on: Feb-2013 Read more
Oral Nucleoside / Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B Am J Gastroenterol. 2013 Jun;108(6):942-8. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. http://www.ncbi.nlm.nih.gov/pubmed/23629601 OBJECTIVES: The long-term outcomes of oral antiviral therapy without hepatitis B immune globulin (HBIG) in prevention of reinfection with hepatitis B after liver transplantation are not known. We aimed to determine the long-term outcomes from a large population of chronic hepatitis B (CHB) liver transplant recipients using oral antiviral therapy alone. Published on: Jun-2013 Read more	International Incidence and Outcomes of Biliary Atresia Journal of Pediatric Gastroenterology & Nutrition. 56(4):344-354, April 2013.doi: 10.1097/MPG.0b013e318282a913 Jimenez-Rivera, Carolina; Jolin-Dahel, Kheira S.; Fortinsky, Kyle J.; Gozdyra, Peter†; Benchimol, Eric I. http://journals.lww.com/jpgn/Abstract/2013/04000/International_Incidence... Abstract Published on: Apr-2013 Read more
B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid Am J Gastroenterol. 2013 Jun;108(6):933-41 B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW. http://www.ncbi.nlm.nih.gov/pubmed/23649186 Published on: Jun-2013 Read more	Levels of Serum Ceruloplasmin Associate With Pediatric Nonalcoholic Fatty Liver Disease Journal of Pediatric Gastroenterology & Nutrition. 56(4):370-375, April 2013.doi: 10.1097/MPG.0b013e31827aced4 Nobili, Valerio; Siotto, Mariacristina‡; Bedogni, Giorgio§; Ravà, Lucilla†; Pietrobattista, Andrea; Panera, Nadia; Alisi, Anna; Squitti, Rosanna\|\| http://journals.lww.com/jpgn/Abstract/2013/04000/Levels_of_Serum_Cerulop... Abstract Published on: Apr-2013 Read more

CLF Intro movie

SMS requests to

9224791366

Ask The Expert

Pediatric Liver Specialists in India

Centres offering Genetic Testing for Pediatric Liver Diseases

Financial Aid Offered by Trusts

Follow us on:

Facebook Twitter YouTube